title: [EFFECTIVENESS OF FULLERENE-(TRIS-AMINOCAPRONIC ACID) HYDRATE IN THE MODEL OF EXPERIMENTAL VIRAL-BACTERIAL PNEUMONIA OF MICE].
abstract: OBJECTIVE
  Study the effectiveness of the substance and various drug formulations of fullerene-(tris-aminocapronic acid) hydrate (FTAAH onwards) in the model of experimental viral-bacterial pneumonia of mice.
  
  
  METHODS
  BALB/c mice were infected with influenza virus A/California/04/2009 and subsequently infected with Staphylococcus aureus. The animals were treated after viral infection with the substance and various drug forms of FTAAH, as well as comparative preparations--oseltamivir and arbidol. Therapy effectiveness was evaluated by clinical indicators (survival, lifespan, animal mass decrease reduction), virological (virus titer), microbiological (density of bacteria in lungs) parameters, confirmed by pathomorphological characteristics of lungs.
  
  
  RESULTS
  FTAAH therapy in injectable form was effective in the model of a combined viral-bacterial pneumonia of mice by all the studied criteria: treatment increased mice survival, reduced the decrease of their body weight, resulted in a reduction of virus titers and density of bacteria in lungs, that correlated with the data from morphological study and signs of bronchopneumonia resolution in mice. FTAAH therapy in rectal form depended on animal infection schemes, as well as preparation dose, increasing with its increase.
  
  
  CONCLUSIONS
  FTAAH substance is effective in the model of experimental viral-bacterial pneumonia of mice.
authors.forename: I N
authors.initials: IN
authors.lastname: Falynskova
authors.forename: E I
authors.initials: EI
authors.lastname: Leonova
authors.forename: I T
authors.initials: IT
authors.lastname: Fedyakina
authors.forename: N R
authors.initials: NR
authors.lastname: Makhmudova
authors.forename: L N
authors.initials: LN
authors.lastname: Lepekha
authors.forename: N A
authors.initials: NA
authors.lastname: Mikhailova
authors.forename: L D
authors.initials: LD
authors.lastname: Rasnetsov
authors.forename: V V
authors.initials: VV
authors.lastname: Zverev
authors.forename: I A
authors.initials: IA
authors.lastname: Leneva
mesh_terms: D000818:Animals; D002626:Chemistry, Pharmaceutical; D004195:Disease Models, Animal; D037741:Fullerenes / Q000008:administration & dosage* / Q000737:chemistry; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000472:pathogenicity; D008168:Lung / Q000382:microbiology / Q000473:pathology / Q000821:virology; D051379:Mice; D053139:Oseltamivir / Q000008:administration & dosage; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology / Q000821:virology; D011024:Pneumonia, Viral / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology / Q000821:virology; D013211:Staphylococcus aureus / Q000472:pathogenicity
chemical_list: D037741:Fullerenes; D053139:Oseltamivir